Skip to main content
Caplight Logo









Emtora Biosciences

Emtora Biosciences

Private
San Antonio, TexasHealthcare & Life Scienceshttps://emtorabio.com/

Last Round

Grant

May 22, 2025

Total Funding Raised

$32.17M

Company Overview

Emtora Biosciences is a clinical-stage biopharmaceutical company that develops eRapa, a proprietary micro-encapsulated formulation of rapamycin for the treatment of cancer and rare genetic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalmTOR inhibitordrug deliveryoncologyrare genetic diseaseclinical trialsdrug developmentFamilial Adenomatous PolyposisFAPnon-muscle invasive bladder cancerNMIBCbiotechdrug licensingprecision medicinepharma pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Emtora Biosciences Comparables

Compare Emtora Biosciences with similar companies based on industry and business-model similarity.

Emtora Biosciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Tornado Therapeutics
77%
Recursion Pharmaceuticals
77%
S.L.A. Pharma AG
75%

Emtora Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 22, 2025
GrantAug 17, 2022
GrantApr 1, 2020
GrantAug 21, 2019
Convertible DebtFeb 28, 2019
Series A
Jun 2, 2015

Emtora Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 22, 2025

    $3M grant received from CPRIT

  • Apr 1, 2020

    Secured $2.8M from the National Cancer Institute.

Emtora Biosciences Filings

Explore SEC and related filing metadata, where available.

Emtora Biosciences filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Emtora Biosciences's valuation, stock price, and market status.

Is Emtora Biosciences a public or private company?

Emtora Biosciences is a private company.

What is the current stock price of Emtora Biosciences?

Emtora Biosciences is a private company with no public stock price. No recent secondary market data is available.

How much is Emtora Biosciences worth (valuation)?

Valuation information for Emtora Biosciences is not publicly available.

Can I buy Emtora Biosciences stock?

Emtora Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Emtora Biosciences's last funding round?

Emtora Biosciences's most recent funding round was Grant on May 22, 2025.

Who are the main investors in Emtora Biosciences?

Key investors in Emtora Biosciences include National Cancer Institute, Cancer Prevention and Research Institute of Texas (CPRIT).

Will Emtora Biosciences IPO soon?

No public IPO plans have been announced for Emtora Biosciences.

How can I track Emtora Biosciences secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Emtora Biosciences's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Antonio, Texas
Employee Range1
Year Founded2012
Last FundingMay 22, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?